Figure 3
Pro-MMP-2/α1(IV)NC1 complex regulates MMP-2 activation.
(a) Regulation of APMA mediated MMP-2 activation. Lane 1, control; Lane 2, treatment with APMA; Lanes 3–5, treatment with APMA and various concentrations of α1(IV)NC1. (b) Regulation of MT1-MMP mediated MMP-2 activation. Lane 1, control; Lane 2, treatment with MT1-MMP; Lanes 3–6, treatment with MT1-MMP and various concentrations of recombinant α1(IV)NC1. Panel (a) and (b) are gelatin zymograms. (c–d) ActiveMMP-2 and proMMP-2 complex with α1(IV)NC1 using 10–30% sucrose ISCO gradient. Various fractions collected were analyzed using antibodies against MMP-2 and α1(IV)NC1. (e) CBD and HPD domains of MMP-2 interactions with α1(IV)NC1. Quantification of relative complex formation of α1(IV)NC1 with MMP-2, CBD and HPD domains. Complex was analyzed by ELISA using anti-α1(IV)NC1 antibody. Results shown are mean ± SD. ***Indicates p<0.002; compared to proMMP-2, *indicates p<0.02; compared to active MMP-2 and **indicates p<0.004; compared to CBD domain.
